1998
Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradiographic study
Elsworth J, Brittan M, Taylor J, Sladek J, Redmond D, Innis R, Zea-Ponce Y, Roth R. Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradiographic study. Brain Research 1998, 795: 55-62. PMID: 9622593, DOI: 10.1016/s0006-8993(98)00252-2.Peer-Reviewed Original ResearchMeSH Keywords1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsAutoradiographyBenzofuransBrain Tissue TransplantationChlorocebus aethiopsCorpus StriatumDisease Models, AnimalDopamine AgentsFetal Tissue TransplantationImage Processing, Computer-AssistedIodine RadioisotopesMesencephalonParkinson Disease, SecondaryRadioligand AssayReceptors, Dopamine D2Up-RegulationConceptsFetal ventral mesencephalonD2 receptor bindingVentral mesencephalonDorsal striatumAutoradiographic studyDopamine uptake site densityPostsynaptic dopamine receptor activationVentral striatumDopamine concentrationsStriatal D2 receptor bindingReceptor bindingD2 receptor upregulationPostsynaptic dopamine transmissionTetrahydropyridine-treated monkeysStriatal D2 receptorsDopamine receptor activationPrevious autoradiographic studiesAfrican green monkeysDonor neuronsIntrastriatal graftingParkinsonian primatesNeural transplantationReceptor upregulationStriatal circuitryMotor function
1997
(S)-(-)-HA-966, a gamma-hydroxybutyrate-like agent, prevents enhanced mesocorticolimbic dopamine metabolism and behavioral correlates of restraint stress, conditioned fear and cocaine sensitization.
Morrow B, Lee E, Taylor J, Elsworth J, Nye H, Roth R. (S)-(-)-HA-966, a gamma-hydroxybutyrate-like agent, prevents enhanced mesocorticolimbic dopamine metabolism and behavioral correlates of restraint stress, conditioned fear and cocaine sensitization. Journal Of Pharmacology And Experimental Therapeutics 1997, 283: 712-21. PMID: 9353390.Peer-Reviewed Original ResearchConceptsHA-966Dopamine metabolismMedial prefrontal cortexCocaine sensitizationNucleus accumbensHigh doseAcute cocaine-induced locomotionPrefrontal cortexGABAB receptor bindingCocaine-induced locomotionGamma-aminobutyric acidStress-induced increaseFear-inducing behaviorDopamine utilizationGABAB receptorsRestraint stressControl ratsLocomotor sensitizationDopaminergic neurotransmissionShell subdivisionBaclofen bindingCortical membranesPositive enantiomerWeight gainReceptor binding
1986
Purification and characterization of tribulin, an endogenous inhibitor of monoamine oxidase and of benzodiazepine receptor binding
Elsworth J, Dewar D, Glover V, Goodwin B, Clow A, Sandler M. Purification and characterization of tribulin, an endogenous inhibitor of monoamine oxidase and of benzodiazepine receptor binding. Journal Of Neural Transmission 1986, 67: 45-56. PMID: 3023548, DOI: 10.1007/bf01243358.Peer-Reviewed Original ResearchConceptsRo-15 1788Benzodiazepine receptor antagonistBenzodiazepine receptor agonistsBenzodiazepine receptor bindingPeripheral benzodiazepine receptor ligandsBenzodiazepine receptor ligandsReceptor antagonistPeripheral receptorsReceptor agonistReceptor bindingEndogenous inhibitorMonoamine oxidaseReceptor ligandsRat liverMAO ATyramine oxidationHuman urineLow molecular weight fractionThin-layer chromatographyTribulinAgonistsAntagonistGABABenzodiazepinesLiver
1985
Tribulin: an endogenous monoamine oxidase inhibitor/benzodiazepine receptor ligand.
Sandler M, Glover V, Clow A, Elsworth J. Tribulin: an endogenous monoamine oxidase inhibitor/benzodiazepine receptor ligand. Progress In Clinical And Biological Research 1985, 192: 359-62. PMID: 3001762.Peer-Reviewed Original ResearchConceptsLactate-induced panic attacksBenzodiazepine receptor bindingBenzodiazepine receptor ligandsBenzodiazepine withdrawalBenzodiazepine receptorsLow molecular weight inhibitorsPanic attacksTribulin outputAnxiety disordersReceptor bindingMonoamine oxidaseReceptor ligandsAnimal brainsWeight inhibitorsHuman plasmaInhibitorsHuman urineTribulinMonoaminesBrainReceptorsUrine
1982
Brain catecholamine metabolites and behavior in morphine withdrawal
Swann A, Elsworth J, Charney D, Jablons D, Roth R, Redmond D, Maas J. Brain catecholamine metabolites and behavior in morphine withdrawal. European Journal Of Pharmacology 1982, 86: 167-175. PMID: 6297931, DOI: 10.1016/0014-2999(82)90314-4.Peer-Reviewed Original ResearchConceptsCatecholamine metabolitesMorphine withdrawal behaviorsBeta-receptor bindingWithdrawal behaviorDebrisoquin sulfateAcute treatmentMorphine withdrawalNorepinephrine metaboliteMorphine pelletsWithdrawal signsPlasma levelsBrain 3Noradrenergic hyperactivityReceptor bindingMHPGBrainMetabolitesNaloxoneHVARatsHyperactivity